References
- Borden E C. Effects of interferons in neoplastic diseases of man. Pharmacol Ther 1988; 37: 213–229
- Foon K A. Biological response modifiers: The new immunotherapy. Cancer Res 1989; 49: 1621–1639
- Strander H, Cantell K, Carlstrom G, et al. Clinical and laboratory investigations on man: Systemic administration of potent interferon to man. J Natl Cancer Inst 1973; 51: 733–794
- Goldstein D, Laszlo J. Interferon therapy in cancer: From imaginon to interferon. Cancer Res 1986; 46: 4315–4329
- Murphy G P. Current report on the interferon program at Rosewell Park Memorial Institute. J Surg Oncol 1981; 17: 99–111
- Rosso R, Nobile M T, Sertoli M R, et al. Antitumoral activity of human fibroblast interferon administered intranodularly. Oncology 1985; 42: 86–88
- Ozzello L, Habif D V, De Rosa C M, et al. Effects of intralesional injections of interferons-a on xenografts of human mammary carcinoma cells (BT 20 and MCF-7). J Interferon Res 1988; 8: 207–215
- Ozzello L, Habif D V, De Rosa C M, et al. Treatment of human breast cancer xenografts using natural interferons- α and - γ injected singly or in combination. J Interferon Res 1988; 8: 679–690
- Ozzello L, Habif D V, De Rosa C M. Antiproliferative effects of natural interferon beta alone and in combination with natural interferon gamma on human breast carcinomas in nude mice. Breast Cancer Res Treat 1990; 26: 89–96
- Ozzello L, Habif D V, De Rosa C M, et al. Cellular events accompanying regression of skin recurrences of breast carcinomas treated with intralesional injections of natural interferons α and γ. Cancer Res 1982; 52: 4571–4581
- Cantell K, Hirvonen S, Morgensen K E, . Human leukocyte interferon: production, purification, stability and animal experiments. The Production and Use of Interferon for the Treatment and Prevention of Human Virus Infections, C Waymouth, et al. Tissue Culture Association, Rockville, MD 1974; 35–38
- Cantell K, Hirvonen S, Kauppinen H-L, et al. Production of interferon in human leukocytes from normal donors with the use of Sendai virus. Methods Enzymol 1981; 78: 29–38
- Cantell K, Hirvonen S, Koistinen V. Partial purification of human leukocyte interferon on a large scale. Methods Enzymol 1981; 78: 499–505
- Wallach D, Cantell K, Hirvonen S, . Presence of tumor necrosis factor and lymphotoxin in clinical interferon preparations derived from leukocytes. The Biology of the Interferon System 1986, K Cantell, H Schellekens, et al. Martinus Nijhoff, DordrechtThe Netherlands 1987; 251–256
- Kauppinen H-L, Bang B, Eronen J, . Preparation of natural human gamma interferon for clinical use. The Biology of the Interferon System 1985, W E Stewart, H Schellekens, et al. Elsevier, Amsterdam 1986; 221–227
- Ceriani R L, Peterson J A, Lee J Y, et al. Characterization of cell surface antigens of normal human mammary epithelial cells with monoclonal antibodies. Somat Cell Genet 1983; 9: 415–427
- Schiller J H, Groveman D S, Schmid S M, et al. Synergistic antiproliferative effects of human recombinant a54- or /3ser-inter-feron with y-interferon on human cell lines of various histogenesis. Cancer Res 1986; 46: 483–488
- Vilcek J, Henriksen-DeStefano D, Palombella V J, . Interaction between tumor necrosis factor and interferons. The Biology of the Interferon System 1985, W E Stewart, H Schellekens, et al. Elsevier, Amsterdam 1986; 249–256
- von Wussow P, Block B, Hartmann F, et al. Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 1988; 61: 1071–1074
- Quesada J R, Talpaz M, Rios A, et al. Clinical toxicity of interferons in cancer patients: A review. 3 Clin Oncol 1986; 4: 234–243
- Gronstein R D, Deak M R, Jacques S L, et al. The systemic administration of gamma interferon inhibits collagen synthesis and acute inflammation in a murine skin wounding model. J Invest Dermatol 1989; 93: 18–27
- Ozzello L, De Rosa C M, Blank E W, et al. The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts. Breast Cancer Res Treat 1993; 25: 265–276